{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:05:52Z","timestamp":1759017952119,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.annder.2017.03.014","type":"journal-article","created":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T22:57:17Z","timestamp":1491519437000},"page":"663-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["L\u2019absence de preuve n\u2019est pas la preuve de l\u2019absence. Du m\u00e9susage de \u00ab\u00a0l\u2019evidence based medicine\u00a0\u00bb"],"prefix":"10.1016","volume":"144","author":[{"given":"J.","family":"Revuz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2017.03.014_bib0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence-based medicine: what it is and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.annder.2017.03.014_bib0075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0002-9343(97)00244-1","article-title":"Problems in the \u201cevidence\u201d of \u201cevidence-based medicine\u201d","volume":"103","author":"Feinstein","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.annder.2017.03.014_bib0080","article-title":"\u00c9ditorial\u00a0: preuve adapt\u00e9e\u00a0: reconna\u00eetre les limites de l\u2019Evidence Based Medicine","volume":"7","author":"Lemiengre","year":"2008","journal-title":"Minerva"},{"key":"10.1016\/j.annder.2017.03.014_bib0085","first-page":"40","article-title":"Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives","volume":"4","author":"Leyden","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.annder.2017.03.014_bib0130","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3855\/jidc.6862","article-title":"In vitro antimicrobial susceptibility patterns of Propionibacterium acnes isolated from patients with acne vulgaris","volume":"10","author":"Biswal","year":"2016","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.annder.2017.03.014_bib0095","first-page":"CD002086","article-title":"Minocycline for acne vulgaris: efficacy and safety","author":"Garner SE1","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.annder.2017.03.014_bib0100","first-page":"CD002086","article-title":"Minocycline for acne vulgaris: efficacy and safety","author":"Garner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.annder.2017.03.014_bib0105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000228334","article-title":"Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients","volume":"219","author":"Gener","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2017.03.014_bib0110","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","article-title":"The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa","volume":"219","author":"van der Zee","year":"2009","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2017.03.014_bib0115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000321716","article-title":"Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa","volume":"222","author":"Join-Lambert","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2017.03.014_bib0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2017.03.014_bib0125","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimbal","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annder.2017.03.014_bib0065","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963817301436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963817301436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:04:59Z","timestamp":1758971099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963817301436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0151963817301436"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2017.03.014","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019absence de preuve n\u2019est pas la preuve de l\u2019absence. Du m\u00e9susage de \u00ab\u00a0l\u2019evidence based medicine\u00a0\u00bb","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2017.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}